EUVIMEDEUVIMED entdecken
Open Access

Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells

Sarah J Wu iD, Sam Sadigh, Andrew A Lane, Geraldine S Pinkus

American Journal of Clinical Pathology · 2023

DOI: 10.1093/ajcp/aqac174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Sarah J Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Boston, MA, US. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, AbbVie, Stemline Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Targeted therapies for blastic plasmacytoid dendritic cell neoplasm (BPDCN) have presented a diagnostic dilemma for differentiating residual BPDCN from reactive plasmacytoid dendritic cells (pDCs) because these conditions have a similar immunoprofile, necessitating discovery of additional diagnostic markers.

Methods

Fifty cases of BPDCN involving bone marrow (26/50) and skin (24/50) as well as other hematologic malignancies (67) and nonneoplastic samples (37) were included. Slides were stained using a double-staining protocol for the following immunohistochemical marker combinations: TCF4/CD123, TCF4/CD56, SOX4/CD123, and IRF8/CD123.

Results

The nuclear marker SOX4 is expressed in neoplastic pDCs; in our cohort, SOX4/CD123 showed 100% sensitivity and 98% specificity in distinguishing BPDCN from reactive pDCs and other neoplasms. TCF4/CD56 had a 96% sensitivity and 100% specificity for BPDCN. IRF8 is a nonspecific marker that is positive in BPDCN and pDCs as well as other myeloid malignancies.

Conclusions

The novel immunohistochemical combination SOX4/CD123 distinguishes BPDCN, including CD56-negative BPDCN, from both reactive pDCs and other neoplasms. Because of their high diagnostic sensitivity and specificity, the double-staining marker combinations TCF4/CD123, TCF4/CD56, and SOX4/CD123 can be used to confirm lineage in BPDCN cases and detect minimal/measurable residual disease in tissue specimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsSkin NeoplasmsHumansInterleukin-3 Receptor alpha SubunitBone MarrowDendritic CellsInterferon Regulatory FactorsSOXC Transcription Factors

Stichwörter der Autor:innen

Blastic plasmacytoid dendritic cell neoplasmImmunohistochemistryMinimal/measurable residual diseasePlasmacytoid dendritic cellsSOX4

Substanzen

Interleukin-3 Receptor alpha SubunitInterferon Regulatory FactorsSOX4 protein, humanSOXC Transcription Factors

Autor:innen und Institutionen

  • Department of Pathology, Brigham and Women's Hospital, Boston, MA, US.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.

ORCID-Profile: Sarah J Wu

Förderung

  • NCI NIH HHS
  • AbbVie
  • Stemline Therapeutics
  • QIAGEN
  • Leukemia and Lymphoma Society
  • NIH

Zitieren

APA

Wu, S. J., Sadigh, S., Lane, A. A., & Pinkus, G. S. (2023). Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqac174

Vancouver

Wu SJ, Sadigh S, Lane AA, Pinkus GS. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqac174

BibTeX
@article{Wu2023,
  author = {Wu, Sarah J and Sadigh, Sam and Lane, Andrew A and Pinkus, Geraldine S},
  title = {Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells},
  journal = {American Journal of Clinical Pathology},
  year = {2023},
  doi = {10.1093/ajcp/aqac174}
}
Kostenlos starten →